Marinus Pharmaceuticals Inc MRNS:NASDAQ

Last Price$5.80NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.03(0.52%)
Bid (Size)$5.22 (3)
Ask (Size)$6.00 (1)
Day Low / High$5.75 - 5.93
Volume146.6 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022


Marinus Pharmaceuticals Inc ( NASDAQ )

Price: $5.80
Change: +0.03 (0.52%)
Volume: 146.6 K
4:00PM ET 8/12/2022

Clovis Oncology Inc ( NASDAQ )

Price: $1.48
Change: +0.03 (2.07%)
Volume: 3.2 M
4:00PM ET 8/12/2022

Allakos Inc ( NASDAQ )

Price: $3.81
Change: +0.21 (5.83%)
Volume: 427.1 K
4:00PM ET 8/12/2022


Price: $20.08
Change: -0.45 (2.19%)
Volume: 79.0 K
4:00PM ET 8/12/2022

Harrow Health Inc ( NASDAQ )

Price: $8.50
Change: -0.04 (0.47%)
Volume: 55.7 K
4:00PM ET 8/12/2022

Read more news Recent News

--Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $23 From $28, Maintains Outperform Rating
10:24AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q2 Revenue $1.79M, vs. Street Est of $2.32M
7:32AM ET 8/11/2022 MT Newswires


Marinus Pharmaceuticals Launches Ztalmy in US for Seizures Associated With CDKL5 Deficiency Disorder
11:25AM ET 7/28/2022 MT Newswires

Marinus Pharmaceuticals (MRNS) said Thursday it commercially launched Ztalmy, or ganaxolone, in the US for the treatment of seizures associated with CDKL5...

Marinus Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher for $110 Million
7:35AM ET 7/14/2022 MT Newswires

Marinus Pharmaceuticals (MRNS) said Thursday that it has entered into a definitive agreement with Novo Nordisk Inc. to sell its Rare Pediatric Disease...

Company Profile

Business DescriptionMarinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA. View company web site for more details
Address5 Radnor Corporate Center
Radnor, Pennsylvania 19087-5279
Number of Employees28
Recent SEC Filing08/11/20228-K
President, Chief Executive Officer & DirectorScott N. Braunstein
Chief Financial Officer & TreasurerSteven E. Pfanstiel
Chief Medical OfficerJoseph Hulihan
Vice President-Marinus TechnologyFred Halperin

Company Highlights

Price Open$5.76
Previous Close$5.77
52 Week Range$3.97 - 13.15
Market Capitalization$215.8 M
Shares Outstanding37.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.89
Beta vs. S&P 500N/A
Net Profit Margin-386.11%
Return on Equity-240.66%

Analyst Ratings as of 06/29/2022

Consensus RecommendationConsensus Icon
Powered by Factset